Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients : An International Web-based Survey
© The Author(s) 2022. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissionsoup.com..
INTRODUCTION: Anti-SARS-CoV-2 vaccine clinical trials did not include patients with immune-mediated conditions such as inflammatory bowel disease [IBD]. We aimed to describe the implementation of anti-SARS-CoV-2 vaccination among IBD patients, patients' concerns, and the side effect profile of the anti-SARS-CoV-2 vaccines, using real-world data.
METHODS: An anonymous web-based self-completed survey was distributed in 36 European countries between June and July 2021. The results of the patient characteristics, concerns, vaccination status, and side effect profile were analysed.
RESULTS: In all 3272 IBD patients completed the survey, 79.6% had received at least one dose of anti-SARS-CoV-2 vaccine, and 71.7% had completed the vaccination process. Patients over 60 years old had a significantly higher rate of vaccination [p < 0.001]. Patients' main concerns before vaccination were the possibility of having worse vaccine-related adverse events due to their IBD [24.6%], an IBD flare after vaccination [21.1%], and reduced vaccine efficacy due to IBD or associated immunosuppression [17.6%]. After the first dose of the vaccine, 72.4% had local symptoms and 51.4% had systemic symptoms [five patients had non-specified thrombosis]. Adverse events were less frequent after the second dose of the vaccine and in older patients. Only a minority of the patients were hospitalised [0.3%], needed a consultation [3.6%], or had to change IBD therapy [13.4%] after anti-SARS-CoV-2 vaccination.
CONCLUSIONS: Although IBD patients raised concerns about the safety and efficacy of anti-SARS-CoV-2 vaccines, the implementation of vaccination in those responding to our survey was high and the adverse events were comparable to the general population, with minimal impact on their IBD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Journal of Crohn's & colitis - 16(2022), 7 vom: 04. Aug., Seite 1070-1078 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ellul, Pierre [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 08.08.2022 Date Revised 09.08.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/ecco-jcc/jjac010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335718337 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335718337 | ||
| 003 | DE-627 | ||
| 005 | 20231225230510.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ecco-jcc/jjac010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1119.xml |
| 035 | |a (DE-627)NLM335718337 | ||
| 035 | |a (NLM)35037033 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ellul, Pierre |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients |b An International Web-based Survey |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.08.2022 | ||
| 500 | |a Date Revised 09.08.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a INTRODUCTION: Anti-SARS-CoV-2 vaccine clinical trials did not include patients with immune-mediated conditions such as inflammatory bowel disease [IBD]. We aimed to describe the implementation of anti-SARS-CoV-2 vaccination among IBD patients, patients' concerns, and the side effect profile of the anti-SARS-CoV-2 vaccines, using real-world data | ||
| 520 | |a METHODS: An anonymous web-based self-completed survey was distributed in 36 European countries between June and July 2021. The results of the patient characteristics, concerns, vaccination status, and side effect profile were analysed | ||
| 520 | |a RESULTS: In all 3272 IBD patients completed the survey, 79.6% had received at least one dose of anti-SARS-CoV-2 vaccine, and 71.7% had completed the vaccination process. Patients over 60 years old had a significantly higher rate of vaccination [p < 0.001]. Patients' main concerns before vaccination were the possibility of having worse vaccine-related adverse events due to their IBD [24.6%], an IBD flare after vaccination [21.1%], and reduced vaccine efficacy due to IBD or associated immunosuppression [17.6%]. After the first dose of the vaccine, 72.4% had local symptoms and 51.4% had systemic symptoms [five patients had non-specified thrombosis]. Adverse events were less frequent after the second dose of the vaccine and in older patients. Only a minority of the patients were hospitalised [0.3%], needed a consultation [3.6%], or had to change IBD therapy [13.4%] after anti-SARS-CoV-2 vaccination | ||
| 520 | |a CONCLUSIONS: Although IBD patients raised concerns about the safety and efficacy of anti-SARS-CoV-2 vaccines, the implementation of vaccination in those responding to our survey was high and the adverse events were comparable to the general population, with minimal impact on their IBD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Inflammatory bowel disease | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a vaccination | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Revés, Joana |e verfasserin |4 aut | |
| 700 | 1 | |a Abreu, Bárbara |e verfasserin |4 aut | |
| 700 | 1 | |a Chaparro, María |e verfasserin |4 aut | |
| 700 | 1 | |a Gisbert, Javier P |e verfasserin |4 aut | |
| 700 | 1 | |a Allocca, Mariangela |e verfasserin |4 aut | |
| 700 | 1 | |a Fiorino, Gionata |e verfasserin |4 aut | |
| 700 | 1 | |a Barberio, Brigida |e verfasserin |4 aut | |
| 700 | 1 | |a Zingone, Fabiana |e verfasserin |4 aut | |
| 700 | 1 | |a Pisani, Anthea |e verfasserin |4 aut | |
| 700 | 1 | |a Cassar, David |e verfasserin |4 aut | |
| 700 | 1 | |a Michalopoulos, George |e verfasserin |4 aut | |
| 700 | 1 | |a Mantzaris, Gerassimos |e verfasserin |4 aut | |
| 700 | 1 | |a Koutroubakis, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Karmiris, Konstantinos |e verfasserin |4 aut | |
| 700 | 1 | |a Katsanos, Konstantinos |e verfasserin |4 aut | |
| 700 | 1 | |a Ďuricova, Dana |e verfasserin |4 aut | |
| 700 | 1 | |a Burisch, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Madsen, Gorm Roager |e verfasserin |4 aut | |
| 700 | 1 | |a Maaser, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Naila, Arebi |e verfasserin |4 aut | |
| 700 | 1 | |a Orfanoudaki, Eleni |e verfasserin |4 aut | |
| 700 | 1 | |a Milivojevic, Vladimir |e verfasserin |4 aut | |
| 700 | 1 | |a Buisson, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Avedano, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Leone, Salvo |e verfasserin |4 aut | |
| 700 | 1 | |a Torres, Joana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Crohn's & colitis |d 2007 |g 16(2022), 7 vom: 04. Aug., Seite 1070-1078 |w (DE-627)NLM204021901 |x 1876-4479 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2022 |g number:7 |g day:04 |g month:08 |g pages:1070-1078 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ecco-jcc/jjac010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2022 |e 7 |b 04 |c 08 |h 1070-1078 | ||